SIRP alpha-PD-L1 targeting bispecific antibody - Shandong Fontacea Pharmaceutical
Latest Information Update: 22 Mar 2024
At a glance
- Originator Shandong Fontacea Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; SIRPA protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Mar 2024 SIRP alpha-PD-L1 targeting bispecific antibody - Shandong Fontacea Pharmaceutical is available for licensing as of 04 Mar 2024. http://www.fontaceapharma.com/col.jsp?id=109
- 04 Mar 2024 Preclinical trials in Cancer in China (Parenteral), prior to March 2024 (Shandong Fontacea Pharmaceutical pipeline, March 2024)